Transine Therapeutics closes seed financing

Country

United Kingdom

A Cambridge, UK company investigating the therapeutic potential of antisense long non-coding RNAs has raised an additional £4.6 million in seed financing to accelerate the development of its product portfolio focused on diseases of the central nervous system and ophthalmology indications. Transine Therapeutics Ltd announced the additional funding on 31 May, bringing total proceeds from the seed round up to £13.7 million. The round was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund.